On the 14th November 2022, just a few days after Imugene...

On the 14th November 2022, just a few days after Imugene announced that the first
IV monotherapy cohort in the MAST trial of Vaxinia had been cleared and 4 months
prior to roadshow presentations in Sydney, Melbourne and Perth, an American media
company Ivanhoe News presented the following medical breakthrough news story -




I have searched the Media thread and I don't think this video has been shared before.
At 1:03 I was amazed to hear Professor Fong announce the groundbreaking news that

"We are convinced that by having this virus we will not only be able to directly
attack the cancer and stimulate our immune system but we will be able to partner
with other agents that also do that and together grow therapies for cancers
that until now have no treatment"

Clearly sounds like Yuman was referring to the potential of onCARlytics to provide a
paradigm shift in the treatment of solid tumors via Car-T therapy combinations.

And to speak with such conviction and four months prior to when comments were
made that caused knee wobbles for some attending the roadshow presentations that
what was seen in preclinical animal trials were now being seen in human trials.

Makes you wonder, what is known today as to the status of clinical trials that cannot yet be disclosed under FDA guidelines or any potential commercial NDA arrangements.


GLTAH - Go Team Imugene

.